Collectively, YAP1 influences CAF biology across multiple stages in prostate cancer—from early lineage activation, to maintenance of late myCAFs, to reprogramming of ECM-CAFs toward immune-activating Lym-CAFs. Here, YAP1 is linked to prostate carcinoma.